Core Viewpoint - Jinkai Biotechnology (301509.SZ) expects a significant increase in net profit for 2025, driven by improved terminal demand and order delivery pace [1] Financial Performance - The company anticipates a net profit attributable to shareholders ranging from 92 million to 116 million yuan, representing a year-on-year growth of 138.28% to 200.45% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 72 million and 91 million yuan, indicating a year-on-year increase of 314.69% to 424.12% [1] Operational Factors - The increase in delivered orders during the reporting period is attributed to the recovery in terminal demand and the rhythm of customer order deliveries [1] - The overall gross profit margin has improved due to the impact of the product structure of delivered orders [1]
金凯生科(301509.SZ)：预计2025年净利润同比增长138.28%～200.45%